Glomerular Filtration Rate and Myeloma Treatment Outcomes
Author Information
Author(s): Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, Treleaven J
Primary Institution: Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Surrey, UK
Hypothesis
Does glomerular filtration rate (GFR) at the time of high-dose melphalan administration correlate with treatment-related toxicity and survival in myeloma patients?
Conclusion
Patients with low GFR at the time of high-dose melphalan had shorter overall survival compared to those with normal GFR.
Supporting Evidence
- 38 patients had a glomerular filtration rate below normal.
- Patients with low GFR had higher rates of oral mucositis, diarrhea, and infections.
- Median overall survival was significantly shorter in patients with low GFR.
Takeaway
Doctors looked at how kidney function affects treatment for myeloma, finding that those with lower kidney function didn't live as long after treatment.
Methodology
The study correlated GFR with treatment-related toxicity, disease progression, and survival in newly diagnosed myeloma patients receiving high-dose melphalan.
Participant Demographics
Median age of participants was 53 years, with a range from 31 to 72 years.
Statistical Information
P-Value
0.015
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website